Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.37 |
| ▸ | RELA | Q04206 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | APLNR | P35414 | 1/20 | 0.35 |
| ▸ | GHSR | Q92847 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | SPR | P35270 | 1/20 | 0.32 |
| ▸ | RET | P07949 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21844115 | 0.90 | GAA (0.40) | GAARORCNFKB1NFKB2RELA | |
| SCHEMBL2087734 | 0.85 | RORC (0.43) | GAARORCNFKB1NFKB2RELA | |
| SCHEMBL23274329 | 0.82 | GAA (0.44) | GAARORCNFKB1NFKB2RELA | |
| SCHEMBL18424709 | 0.82 | RORC (0.39) | GAARORCNFKB1NFKB2RELA | |
| SCHEMBL17520236 | 0.82 | RORC (0.39) | GAARORCNFKB1NFKB2RELA | |
| SCHEMBL25521432 | 0.81 | GAA (0.39) | GAARORCNFKB1NFKB2RELA | |
| SCHEMBL26012490 | 0.81 | GAA (0.36) | GAARORCNFKB1NFKB2RELA | |
| Hydrochloric Acid SCHEMBL28132627 | 0.80 | RORC (0.39) | GAARORCNFKB1NFKB2RELA | |
| SCHEMBL24572117 | 0.80 | RORC (0.39) | GAARORCNFKB1NFKB2RELA | |
| SCHEMBL26018305 | 0.80 | RORC (0.39) | GAARORCNFKB1NFKB2RELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479818-B2 | Treatment of fibrosis with IRE1 small molecule inhibitors | CORNELL UNIVERSITY (US) | 2025-11-25 | — | — | US | disclosed |
| US-20250188069-A1 | COMPOUNDS AND METHODS FOR DEGRADING CASEIN KINASE 1 ALPHA | PIN THERAPEUTICS, INC. (KR) | 2025-06-12 | — | — | US | disclosed |
| EP-4558137-A2 | CHROMANE AMIDINE MONOBACTAM COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | Merck Sharp & Dohme LLC (US) | 2025-05-28 | — | — | EP | disclosed |
| US-12312336-B2 | Inhibitors of RAF kinases | Pierre Fabre Médicament (FR) | 2025-05-27 | — | — | US | disclosed |
| EP-3707126-B1 | IRE1 SMALL MOLECULE INHIBITORS | UNIV CORNELL (US) | 2025-05-14 | — | — | EP | disclosed |
| WO-2025097104-A1 | THIENYL COMPOUNDS FOR THE TREATMENT OF A CENTRAL NERVOUS SYSTEM DISEASE OR DISORDER | PGI DRUG DISCOVERY LLC (US) | 2025-05-08 | — | — | WO | disclosed |
| EP-4543868-A1 | COMPOUNDS AND METHODS FOR DEGRADING CASEIN KINASE 1 ALPHA | Pin Therapeutics, Inc. (KR) | 2025-04-30 | — | — | EP | disclosed |
| US-20250019376-A1 | CHROMANE AMIDINE MONOBACTAM ANTIBIOTICS | MERCK SHARP & DOHME LLC (US) | 2025-01-16 | — | — | US | disclosed |
| US-20240425477-A1 | IRE1 SMALL MOLECULE INHIBITORS | CORNELL UNIVERSITY | 2024-12-26 | — | — | US | disclosed |
| US-20240360114-A1 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2024-10-31 | — | — | US | disclosed |
| WO-2005033099-A2 | NOVEL DIPEPTIDYL PEPTIDASE IV INHIBITORS; PROCESSES FOR THEIR PREPARATION AND COMPOSITIONS THEREOF | GLENMARK PHARMACEUTICALS LTD. (US) | 2005-04-14 | — | — | WO | disclosed |
| US-20050054678-A1 | Nitrogenous five-membered ring compounds | TANABE SEIYAKU CO., LTD. (JP) | 2005-03-10 | — | — | US | disclosed |
| US-6849622-B2 | Aliphatic nitrogenous five-membered ring compounds | TANABE SEIYAKU CO., LTD. (JP) | 2005-02-01 | — | — | US | disclosed |
| WO-2004099185-A1 | 2-CYANOPYRROLIDINE DERIVATIVES AND THEIR USE AS DPP-IV INHIBITORS | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2004-11-18 | — | — | WO | disclosed |
| US-20040229926-A1 | Aliphatic nitrogen - containing 5 - membered ring compound | TANABE SEIYAKU CO., LTD. | 2004-11-18 | — | — | US | disclosed |
| US-20040063935-A1 | Aliphatic nitrogenous five-membered ring compounds | TANABE SEIYAKU CO., LTD. (JP) | 2004-04-01 | — | — | US | disclosed |
| CN-1468217-A | Aliphatic nitrogenous five-membered ring compounds | ������ҩ��ʽ���� | 2004-01-14 | — | — | CN | disclosed |
| CN-1468216-A | Nitrogenous five-membered ring compound | ������ҩ��ʽ���� | 2004-01-14 | — | — | CN | disclosed |
| EP-1325910-A1 | ALIPHATIC NITROGENOUS FIVE-MEMBERED RING COMPOUNDS | TANABE SEIYAKU CO., LTD. (JP) | 2003-07-09 | — | — | EP | disclosed |
| EP-1323710-A1 | NITROGENOUS FIVE-MEMBERED RING COMPOUNDS | Tanabe Seiyaku Co., Ltd. (JP) | 2003-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063935-A1 | Aliphatic nitrogenous five-membered ring compounds | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SCN5A, CYP11B1 | GAA 2920/4885RORC 1244/4885NFKB1 492/4885 |
| US-20240425477-A1 | IRE1 SMALL MOLECULE INHIBITORS | XBP1, ERN2, ERN1 | GAA 1747/4885RORC 3226/4885NFKB1 1874/4885 |
| US-20250019376-A1 | CHROMANE AMIDINE MONOBACTAM ANTIBIOTICS | PAM, ACMSD, MGAM2 | GAA 782/4885RORC 1724/4885NFKB1 410/4885 |
| US-20240360114-A1 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | AIFM2, GPX1, GPX4 | GAA 771/4885RORC 1457/4885NFKB1 962/4885 |
| US-20050054678-A1 | Nitrogenous five-membered ring compounds | ALK, NPR1, SCO2 | GAA 4346/4885RORC 2364/4885NFKB1 2978/4885 |
| US-12479818-B2 | Treatment of fibrosis with IRE1 small molecule inhibitors | XBP1, DDIT3, HSP90B1 | GAA 2332/4885RORC 2242/4885NFKB1 2092/4885 |
| US-20250188069-A1 | COMPOUNDS AND METHODS FOR DEGRADING CASEIN KINASE 1 ALPHA | CSNK1A1, CSNK1G1, CSNK2A1 | GAA 84/4885RORC 2419/4885NFKB1 948/4885 |
| US-12312336-B2 | Inhibitors of RAF kinases | BRAF, RAF1, ARAF | GAA 1754/4885RORC 594/4885NFKB1 1350/4885 |
| US-20040229926-A1 | Aliphatic nitrogen - containing 5 - membered ring compound | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP11B1, CYP11B2 | GAA 3354/4885RORC 1428/4885NFKB1 835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.